open access

Ahead of Print
Letter to the Editor
Published online: 2020-12-17
Submitted: 2020-08-28
Accepted: 2020-09-22
Get Citation

New twist to an old problem: COVID-19 and idiopathic pulmonary fibrosis

Pratap Upadhya, Ravindra Chary, Gopal Chawla, Rohit Vadala, Madhusmita Mohanty
DOI: 10.5603/ARM.a2020.0177

open access

Ahead of Print
LETTERS
Published online: 2020-12-17
Submitted: 2020-08-28
Accepted: 2020-09-22

Abstract

Iidiopathic pulmonary fibrosis (IPF) diagnosis and treatment during this COVID-19 pandemic have been affected. COVID-19 has not only impacted the prognosis of these patients but also the approach to these patients. Pulmonary function tests (PFT) and lung biopsies are less encouraged now. Traditional antifibrotics used in IPF should be encouraged irrespective of patient lung function and in those with non-definite usual interstitial pneumonia in high resolution computed tomography.

Abstract

Iidiopathic pulmonary fibrosis (IPF) diagnosis and treatment during this COVID-19 pandemic have been affected. COVID-19 has not only impacted the prognosis of these patients but also the approach to these patients. Pulmonary function tests (PFT) and lung biopsies are less encouraged now. Traditional antifibrotics used in IPF should be encouraged irrespective of patient lung function and in those with non-definite usual interstitial pneumonia in high resolution computed tomography.

Get Citation

Keywords

idiopathic pulmonary fibrosis; COVID-19; interstitial lung disease; pirfenidone

About this article
Title

New twist to an old problem: COVID-19 and idiopathic pulmonary fibrosis

Journal

Advances in Respiratory Medicine

Issue

Ahead of Print

Article type

Letter to the Editor

Published online

2020-12-17

DOI

10.5603/ARM.a2020.0177

Keywords

idiopathic pulmonary fibrosis
COVID-19
interstitial lung disease
pirfenidone

Authors

Pratap Upadhya
Ravindra Chary
Gopal Chawla
Rohit Vadala
Madhusmita Mohanty

References (9)
  1. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020; 323(14): 1335.
  2. Nathan SD, Costabel U, Albera C, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med. 2019; 153: 44–51.
  3. Fisher JH, Shapera S, To T, et al. Procedure volume and mortality after surgical lung biopsy in interstitial lung disease. Eur Respir J. 2019; 53(2).
  4. Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019; 381(18): 1718–1727.
  5. Wootton SC, Kim DS, Kondoh Y, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 183(12): 1698–1702.
  6. Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017; 5(1): 33–41.
  7. Fragkou PC, Belhadi D, Peiffer-Smadja N, et al. Review of trials currently testing treatment and prevention of COVID-19. Clin Microbiol Infect. 2020; 26(8): 988–998.
  8. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18(5): 1094–1099.
  9. Lancaster LH, Valenzuela C, Mason W, et al. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014; 108(7): 1023–1030.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl